Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017

Coping intervention ineffective for reducing anxiety in siblings of children with cancer

09 Apr 2018

The Siblings Coping Together (SibCT) group intervention method does not appear to have significant positive effects on anxiety symptoms of siblings of children with cancer, a recent study has shown.

The researchers randomized 75 healthy siblings (aged 7–16 years; 41 males) of paediatric cancer patients to either the SibCT treatment (n=41) or to attention control (n=34). Study outcome was anxiety symptoms, measured using the Multidimensional Anxiety Scale for Children (MASC).

SibCT had no significant effect on the total MASC score or on the scores in the individual subsets. Scores were unaffected when analysed according to participant group or across time. At baseline, 28 percent of males and 17 percent of females had elevated MASC scores, though the difference did not reach statistical significance.

Multivariable analysis showed that there was a significant gender influence, such that MASC scores were significantly higher in the male vs female siblings across both groups and all assessment times (p<0.05).

Researchers also assessed the effect of SibCT on caregiver anxiety and found that there was a significant medium-sized reduction in anxiety symptoms over time, according to the total Multidimensional Anxiety Questionnaire (MAQ) scores (p<0.02). However, no significant group-by-time effect was observed.

Additionally, caregiver scores in the physiological/panic subscale of the MAQ were significantly higher when the child with cancer was actively receiving treatment than when off treatment (p<0.04). Analysis by treatment group showed that, when the ill child is on active treatment, caregivers of siblings receiving SibCT had significantly fewer panic reactions than their counterparts in the control group (p<0.03).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017